Open Access

Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study

  • Authors:
    • Jue Zhang
    • Chao Chen
    • Zhaojun Xia
    • Xi Xiong
    • Ping Liu
    • Yanping Xu
    • Xiufeng Liu
    • Zixiong Li
  • View Affiliations

  • Published online on: June 28, 2024     https://doi.org/10.3892/ol.2024.14544
  • Article Number: 410
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Advanced liver cancer is the most common malignant tumor in the elderly, but it also occurs in young people in areas where hepatitis B virus is prevalent. The aim of the present study was to assess the efficacy of systemic antitumor therapy in young patients with advanced liver cancer and investigate the influencing factors. The baseline demographic and clinical data of 38 young patients (≤35 years old) with liver cancer were collected as group A and that of 79 elderly patients (≥55 years old) with liver cancer were collected as group B. There were no significant between‑group differences regarding the proportion of patients with increased serum aspartate aminotransferase, low serum albumin, increased α‑fetoprotein (AFP) and high Child‑Pugh score. The median (m)PFS time in groups A and B was 3.9 and 8.3 months, respectively [hazard ratio (HR), 1.702; P=0.009]. The mOS in group A (17.6 months) was 12.4 months shorter than that in group B (HR, 1.799; P=0.010). In the subgroup analysis, male sex [HR, 1.73; 95% confidence interval (CI), 1.07‑2.79], pathological diagnosis (HR, 1.79; 95% CI, 1.10‑2.91), previous surgical treatment (HR, 2.16; 95% CI, 1.18‑3.95), no tumor thrombus (HR, 2.45; 95% CI, 1.22‑4.93), increased alanine aminotransferase (HR, 2.23; 95% CI, 1.07‑4.65), increased aspartate aminotransferase (HR, 3.22; 95% CI, 1.62‑6.39), normal total bilirubin (HR, 1.77; 95% CI, 1.09‑2.87) and increased AFP (HR, 2.02; 95% CI, 1.19‑3.41) were associated with shorter survival time in group A compared with those in group B (P<0.05). Group A also had a higher incidence of hyper‑progressive disease (HPD) (31.6 vs. 3.8%; P<0.001). HPD was a risk factor for advanced liver cancer (HR, 4.530; 95% CI, 2.251‑9.115; P<0.001]. In conclusion, the efficacy of systemic antitumor therapy in young patients was poorer compared with that in elderly patients. Young patients with liver cancer had a high HBV infection rate and were prone to HPD.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang J, Chen C, Xia Z, Xiong X, Liu P, Xu Y, Liu X and Li Z: Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study. Oncol Lett 28: 410, 2024.
APA
Zhang, J., Chen, C., Xia, Z., Xiong, X., Liu, P., Xu, Y. ... Li, Z. (2024). Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study. Oncology Letters, 28, 410. https://doi.org/10.3892/ol.2024.14544
MLA
Zhang, J., Chen, C., Xia, Z., Xiong, X., Liu, P., Xu, Y., Liu, X., Li, Z."Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study". Oncology Letters 28.3 (2024): 410.
Chicago
Zhang, J., Chen, C., Xia, Z., Xiong, X., Liu, P., Xu, Y., Liu, X., Li, Z."Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study". Oncology Letters 28, no. 3 (2024): 410. https://doi.org/10.3892/ol.2024.14544